Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells

Ren In You, Ching Liang Ho, Hsiu Man Hung, Tsu Yi Chao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drug resistance is a key contributor for treatment failure in hematologic and other malignancies. Nilotinib has been observed with significant activity in patients with chronic phase chronic myeloid leukemia (CML) who have failed or are intolerant of imatinib therapy. Recent reports have suggested that microRNA (miRNA) expression changes are involved in the drug response of human cancer. Several miRNAs have been previously found to be consistently deregulated in imatinib resistance; however, very limited information is available for nilotinib-treated patients who have failed imatinib therapy. Many reports have discovered circulating miRNAs as noninvasive biomarkers of disease and therapy response. The aim of this study was to explore miRNA regulation and find candidate miRNA markers for CML that can be used for drug response prediction. Here we demonstrate the circulating miRNA profile in the culture supernatant of imatinib-resistant K562 CML cells (K562-R) by microarray chip analysis. We have identified specific miRNAs that are associated with nilotinib sensitivity by comparison of miRNA expression patterns from the culture supernatant of nilotinib-treated K562-R cells with the culture supernatant of untreated K562-R cells. The information obtained from this study may have the potential to become a novel biomarker to predict drug response in the future and can also be applied to developing novel therapeutic treatment for CML.

Original languageEnglish
Pages (from-to)71-73
Number of pages3
JournalBiomarkers and Genomic Medicine
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Biomarkers
Myeloid Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MicroRNAs
Microarrays
K562 Cells
Pharmaceutical Preparations
Leukemia, Myeloid, Chronic Phase
Therapeutics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Hematologic Neoplasms
Microarray Analysis
Treatment Failure
Drug Resistance
Cell Culture Techniques

Keywords

  • Chronic myeloid leukemia
  • Imatinib-resistant
  • MiRNAs
  • Nilotinib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biomedical Engineering
  • Medicine(all)
  • Drug Discovery

Cite this

Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells. / You, Ren In; Ho, Ching Liang; Hung, Hsiu Man; Chao, Tsu Yi.

In: Biomarkers and Genomic Medicine, Vol. 5, No. 3, 09.2013, p. 71-73.

Research output: Contribution to journalArticle

@article{c922e02da23f414fac60ffee75848be8,
title = "Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells",
abstract = "Drug resistance is a key contributor for treatment failure in hematologic and other malignancies. Nilotinib has been observed with significant activity in patients with chronic phase chronic myeloid leukemia (CML) who have failed or are intolerant of imatinib therapy. Recent reports have suggested that microRNA (miRNA) expression changes are involved in the drug response of human cancer. Several miRNAs have been previously found to be consistently deregulated in imatinib resistance; however, very limited information is available for nilotinib-treated patients who have failed imatinib therapy. Many reports have discovered circulating miRNAs as noninvasive biomarkers of disease and therapy response. The aim of this study was to explore miRNA regulation and find candidate miRNA markers for CML that can be used for drug response prediction. Here we demonstrate the circulating miRNA profile in the culture supernatant of imatinib-resistant K562 CML cells (K562-R) by microarray chip analysis. We have identified specific miRNAs that are associated with nilotinib sensitivity by comparison of miRNA expression patterns from the culture supernatant of nilotinib-treated K562-R cells with the culture supernatant of untreated K562-R cells. The information obtained from this study may have the potential to become a novel biomarker to predict drug response in the future and can also be applied to developing novel therapeutic treatment for CML.",
keywords = "Chronic myeloid leukemia, Imatinib-resistant, MiRNAs, Nilotinib",
author = "You, {Ren In} and Ho, {Ching Liang} and Hung, {Hsiu Man} and Chao, {Tsu Yi}",
year = "2013",
month = "9",
doi = "10.1016/j.bgm.2013.07.002",
language = "English",
volume = "5",
pages = "71--73",
journal = "Genomic Medicine, Biomarkers, and Health Sciences",
issn = "2214-0247",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells

AU - You, Ren In

AU - Ho, Ching Liang

AU - Hung, Hsiu Man

AU - Chao, Tsu Yi

PY - 2013/9

Y1 - 2013/9

N2 - Drug resistance is a key contributor for treatment failure in hematologic and other malignancies. Nilotinib has been observed with significant activity in patients with chronic phase chronic myeloid leukemia (CML) who have failed or are intolerant of imatinib therapy. Recent reports have suggested that microRNA (miRNA) expression changes are involved in the drug response of human cancer. Several miRNAs have been previously found to be consistently deregulated in imatinib resistance; however, very limited information is available for nilotinib-treated patients who have failed imatinib therapy. Many reports have discovered circulating miRNAs as noninvasive biomarkers of disease and therapy response. The aim of this study was to explore miRNA regulation and find candidate miRNA markers for CML that can be used for drug response prediction. Here we demonstrate the circulating miRNA profile in the culture supernatant of imatinib-resistant K562 CML cells (K562-R) by microarray chip analysis. We have identified specific miRNAs that are associated with nilotinib sensitivity by comparison of miRNA expression patterns from the culture supernatant of nilotinib-treated K562-R cells with the culture supernatant of untreated K562-R cells. The information obtained from this study may have the potential to become a novel biomarker to predict drug response in the future and can also be applied to developing novel therapeutic treatment for CML.

AB - Drug resistance is a key contributor for treatment failure in hematologic and other malignancies. Nilotinib has been observed with significant activity in patients with chronic phase chronic myeloid leukemia (CML) who have failed or are intolerant of imatinib therapy. Recent reports have suggested that microRNA (miRNA) expression changes are involved in the drug response of human cancer. Several miRNAs have been previously found to be consistently deregulated in imatinib resistance; however, very limited information is available for nilotinib-treated patients who have failed imatinib therapy. Many reports have discovered circulating miRNAs as noninvasive biomarkers of disease and therapy response. The aim of this study was to explore miRNA regulation and find candidate miRNA markers for CML that can be used for drug response prediction. Here we demonstrate the circulating miRNA profile in the culture supernatant of imatinib-resistant K562 CML cells (K562-R) by microarray chip analysis. We have identified specific miRNAs that are associated with nilotinib sensitivity by comparison of miRNA expression patterns from the culture supernatant of nilotinib-treated K562-R cells with the culture supernatant of untreated K562-R cells. The information obtained from this study may have the potential to become a novel biomarker to predict drug response in the future and can also be applied to developing novel therapeutic treatment for CML.

KW - Chronic myeloid leukemia

KW - Imatinib-resistant

KW - MiRNAs

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=84885191862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885191862&partnerID=8YFLogxK

U2 - 10.1016/j.bgm.2013.07.002

DO - 10.1016/j.bgm.2013.07.002

M3 - Article

VL - 5

SP - 71

EP - 73

JO - Genomic Medicine, Biomarkers, and Health Sciences

JF - Genomic Medicine, Biomarkers, and Health Sciences

SN - 2214-0247

IS - 3

ER -